Pregnancy Clinical Trial
— VitDTrackingOfficial title:
Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome Indicators in the Alentejo Region
The VitDTracking study focuses on the relevance of maternal vitamin D levels and their association with prematurity, aiming to improve maternal and child health outcomes, particularly by reducing avoidable preterm births. In Portugal, vitamin D levels during pregnancy have never been studied. Epidemiological data from other countries reveal a high prevalence of vitamin D deficiency/insufficiency, especially in pregnant women. The hypovitaminoses prevalence remains high even with a supplementation dosage of 400 to 600 IU/day during pregnancy (dosage used in Portugal), which is considered as a suboptimal dose. This phenomenon is associated with adverse maternal and child outcomes, such as intrauterine growth restriction, preeclampsia, cholestasis, hypertension, and gestational diabetes as major causes of prematurity. Additionally, the Portuguese population has a higher prevalence of genome alterations that confer a lower capacity to produce vitamin D from sunlight exposure. These genetic characteristics are present in about 19% of the population, representing a prevalence four times higher than the European average (19% versus 4.75%), leading to a higher predisposition to vitamin D deficiency.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Pregnant women's living in the Alentejo region aged 16 years or older, who after disclosure and clarification of doubts, agree to participate in the study with signed informed consent. Exclusion Criteria: - Language barrier (lack of basic understanding of Portuguese). |
Country | Name | City | State |
---|---|---|---|
Portugal | Unidade Local de Saúde do Baixo Alentejo | Beja | |
Portugal | Unidade Local de Saúde do Alentejo Central - Hospital Espirito Santo de Évora | Évora | |
Portugal | Unidade Local de Saúde do Norte Alentejano | Portalegre |
Lead Sponsor | Collaborator |
---|---|
University of Évora | Comprehensive Health Research Centre, Instituto de Engenharia de Sistemas e Computadores - Inovação e Desenvolvimento de Lisboa (INESC-ID), Unidade Local de Saúde do Alentejo Central, Unidade local de Saúde do Baixo Alentejano, Unidade Local De Saúde Do Norte Alentejano, Universidade Nova de Lisboa |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in the rate of Prematurity with different maternal Vitamin D levels | Prematurity Rate in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in Birth Weight with different maternal Vitamin D levels | Birth Weight in grams | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in Apgar Scores with different maternal Vitamin D levels | Apgar Scores in Scale (<7 or =7) | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the number of admissions to the Neonatal Intensive Care Unit with different maternal Vitamin D levels | Number of admissions to the Neonatal Intensive Care Unit in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the Neonatal Morbidity rate with different maternal Vitamin D levels | Neonatal Morbidity rate in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the Neonatal Mortality rate with different maternal Vitamin D levels | Neonatal Mortality rate in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the number of Neonatal Infections with different maternal Vitamin D levels | Number of Neonatal Infections in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the Number of Congenital Malformation diagnoses with different maternal vitamin D levels | Number of Congenital Malformation diagnoses in percentage | Blood samples will be taken from pregnant women up to the 13th week of pregnancy and then at the second collection point up to 48 hours after the birth (after participant enrollment; two collection points) | |
Primary | Differences in the presence of vitamin D-related polymorphisms with different maternal levels of vitamin D | Differences will be assessed following the defined outcome indicators related to prematurity | Saliva samples from pregnant women will be collected during admission to the hospital or up to 48 hours after delivery (after participant enrollment; single collection point) | |
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to prematurity | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to birth weight | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to Apgar scores | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to admission to the Neonatal Intensive Care Unit | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal morbidity | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal mortality | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to neonatal infections. | Through study completion, an average of 3 months | ||
Secondary | Differences in maternal vitamin D levels between the three groups/cohorts related to the diagnosis of congenital malformations | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with prematurity | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with birth weight | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with Apgar scores | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with admission to the Neonatal Intensive Care Unit. | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal morbidity | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal mortality | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with neonatal infections | Through study completion, an average of 3 months | ||
Secondary | Differences in the presence of vitamin D-related polymorphisms between the three groups/cohorts associated with the diagnosis of congenital malformations | Through study completion, an average of 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |